Georgi is the managing partner at BrightCap Ventures. His background includes operational and product marketing leadership at Honeywell, alongside co-founding Aviaso.
The funding round will support the development of hospital-ready diagnostic products and broaden clinical access to glycan testing.
"Together with genetics, the concept of personalised medicine requires a dynamic approach. Genomics provides the blueprint of where we begin, but health is not static—it evolves with time, environment, and lifestyle. To truly transform care, we must complement genomic insights with modifiable biomarkers: biological signals that capture real-time responses to interventions and track improvement longitudinally. This synergy between genomics and adaptive biomarkers is the cornerstone for turning personalised medicine from a descriptive concept into actionable, measurable, and preventative healthcare."
The pre-seed investment was led by BrightCap Ventures and will support product development and customer acquisition.
"Building in a pandemic, in the midst of lockdowns has been super-interesting. We found customers to validate the concept with and with more time and feedback, we’ve been able to accelerate product and commercial discussions. Having Georgi from BrightCap as an investor and adviser has been an important milestone since my first conversation with him. With this funding, we will continue to build the deep-tech concept and solve a problem that’s costing industries billions annually."
